Corify Care raises €6M to revolutionise cardiac care

Corify Care, a Spanish start-up supported by EIT Health, has secured €6 million in funding to scale its cutting-edge cardiac mapping technology across Europe.

This milestone funding includes €3 million from a private investment round led by Clave-Mondragón and an additional €3 million in public grants. The investment marks a significant step in transforming the diagnosis and treatment of cardiac arrhythmias, a condition that affects millions and is poised to become a major global health challenge.

Cardiac arrhythmias, such as atrial fibrillation (AF), impact millions of lives globally, with potentially severe consequences like strokes and heart failure. In Europe alone, projections suggest that 17.9 million people will suffer from AF by 2060.[1]  Yet, existing cardiac mapping methods remain invasive, time-consuming, and uncomfortable for patients.

Corify Care’s ACORYS system offers a groundbreaking alternative. This non-invasive technology utilises 128 body surface sensors to create highly detailed, real-time electroanatomic heart maps without the need for CT scans or MRIs. By streamlining the process, ACORYS empowers clinicians to diagnose arrhythmias accurately and plan procedures like AF ablation and pacemaker implantation with precision and efficiency.

Evidence of Clinical Impact

Recent clinical studies underscore the transformative potential of ACORYS. The system demonstrated an 88.9% success rate for patients undergoing AF ablation in comparison to a 48% success rate using traditional approaches outside the pulmonary veins.[2] By offering deeper insights into arrhythmia circuits before catheter insertion, ACORYS not only optimises clinical outcomes but also significantly enhances the patient experience.

A Partnership with EIT Health

Since its founding, Corify Care has benefited from the extensive support of EIT Health. From navigating complex regulatory landscapes to securing funding and fostering connections with key stakeholders, EIT Health has been instrumental in Corify’s journey. In 2020, Corify’s technology was recognised as Europe’s most innovative, and in 2022, EIT Health financed the SAVE-COR (ACORYS) project with over €2.5 million, enabling pivotal clinical trials involving more than 1,000 patients across Spain and Portugal. This work laid the foundation for Corify Care obtaining the CE Mark under Europe’s rigorous Medical Device Regulation (MDR), achieved in July 2024.

A Vision for the Future

The latest €6 million funding injection will enable Corify to expand the deployment of ACORYS across Europe and position the company for entry into the U.S. market, with FDA approval expected in the coming months. In parallel, the startup is developing ACORYS 2.0, a next-generation system that integrates digital twins and artificial intelligence to further personalise arrhythmia diagnosis and treatment.

These innovations solidify Corify Care’s position as a leader in cardiac health and herald a new era in global cardiac mapping.

EIT Health’s innovation projects and programmes help start-ups like Corify Care to access funding and achieve key milestones which accelerate their journey to market access.

[1] Lippi, G., Sanchis-Gomar, F., Cervellin, G. (2021). Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. International Journal of Stroke, 16(2), 217-221.

[2] Invers-Rubio, E. et al. (2024) Regional conduction velocities determined by noninvasive mapping are associated with arrhythmia-free survival after atrial fibrillation ablation. Available at: https://pubmed.ncbi.nlm.nih.gov/38636930/ (Accessed 13 December 2024).